Unlike growth hormone, which would worsen glycemic control, AOD-9604 can be used in these populations without concerns about blood sugar elevation or insulin resistance progression
Properly stored at room temperature (1530C), it maintains sterility and composition
Research sponsored by Eli Lilly and Company has shown a higher ratio of Cmax in the abdomen (1.25) compared to 0.8 in the thighs
Consult a licensed clinician before beginning any peptide protocol
Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
